LON:MDC

Mediclinic International Competitors

GBX 305.40
+6.60 (+2.21 %)
(As of 05/6/2021 12:00 AM ET)
Add
Compare
Today's Range
299
306.60
50-Day Range
282.60
319
52-Week Range
241.40
343
Volume756,993 shs
Average Volume491,333 shs
Market Capitalization£2.25 billion
P/E RatioN/A
Dividend Yield3.12%
BetaN/A

Competitors

Mediclinic International (LON:MDC) Vs. HIK, CTEC, DPH, ABC, GNS, and BTG

Should you be buying MDC stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Mediclinic International, including Hikma Pharmaceuticals (HIK), ConvaTec Group (CTEC), Dechra Pharmaceuticals (DPH), Abcam (ABC), Genus (GNS), and BTG (BTG).

Mediclinic International (LON:MDC) and Hikma Pharmaceuticals (LON:HIK) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, earnings, risk and institutional ownership.

Profitability

This table compares Mediclinic International and Hikma Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mediclinic InternationalN/AN/AN/A
Hikma PharmaceuticalsN/AN/AN/A

Valuation and Earnings

This table compares Mediclinic International and Hikma Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mediclinic International£2.98 billion0.76N/AGBX (56.20)-5.43
Hikma Pharmaceuticals£2.34 billion2.29N/AGBX 131.1017.72

Mediclinic International is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Mediclinic International and Hikma Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mediclinic International03102.25
Hikma Pharmaceuticals00403.00

Mediclinic International presently has a consensus price target of GBX 301, indicating a potential downside of 1.44%. Hikma Pharmaceuticals has a consensus price target of GBX 2,730, indicating a potential upside of 17.52%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Hikma Pharmaceuticals is more favorable than Mediclinic International.

Dividends

Mediclinic International pays an annual dividend of GBX 0.03 per share and has a dividend yield of 0.0%. Hikma Pharmaceuticals pays an annual dividend of GBX 0.46 per share and has a dividend yield of 0.0%. Mediclinic International pays out -0.1% of its earnings in the form of a dividend. Hikma Pharmaceuticals pays out 0.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Hikma Pharmaceuticals beats Mediclinic International on 7 of the 9 factors compared between the two stocks.

Mediclinic International (LON:MDC) and ConvaTec Group (LON:CTEC) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership.

Profitability

This table compares Mediclinic International and ConvaTec Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mediclinic InternationalN/AN/AN/A
ConvaTec GroupN/AN/AN/A

Earnings and Valuation

This table compares Mediclinic International and ConvaTec Group's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mediclinic International£2.98 billion0.76N/AGBX (56.20)-5.43
ConvaTec Group£1.89 billion2.44N/AGBX 4.1056.22

Mediclinic International is trading at a lower price-to-earnings ratio than ConvaTec Group, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Mediclinic International and ConvaTec Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mediclinic International03102.25
ConvaTec Group25202.00

Mediclinic International presently has a consensus target price of GBX 301, suggesting a potential downside of 1.44%. ConvaTec Group has a consensus target price of GBX 204.14, suggesting a potential downside of 11.43%. Given Mediclinic International's stronger consensus rating and higher probable upside, analysts clearly believe Mediclinic International is more favorable than ConvaTec Group.

Dividends

Mediclinic International pays an annual dividend of GBX 0.03 per share and has a dividend yield of 0.0%. ConvaTec Group pays an annual dividend of GBX 0.06 per share and has a dividend yield of 0.0%. Mediclinic International pays out -0.1% of its earnings in the form of a dividend. ConvaTec Group pays out 1.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

ConvaTec Group beats Mediclinic International on 5 of the 9 factors compared between the two stocks.

Mediclinic International (LON:MDC) and Dechra Pharmaceuticals (LON:DPH) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership.

Profitability

This table compares Mediclinic International and Dechra Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mediclinic InternationalN/AN/AN/A
Dechra PharmaceuticalsN/AN/AN/A

Earnings and Valuation

This table compares Mediclinic International and Dechra Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mediclinic International£2.98 billion0.76N/AGBX (56.20)-5.43
Dechra Pharmaceuticals£566.40 million7.86N/AGBX 41.4099.37

Mediclinic International is trading at a lower price-to-earnings ratio than Dechra Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Mediclinic International and Dechra Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mediclinic International03102.25
Dechra Pharmaceuticals01202.67

Mediclinic International presently has a consensus target price of GBX 301, suggesting a potential downside of 1.44%. Dechra Pharmaceuticals has a consensus target price of GBX 3,438.33, suggesting a potential downside of 16.42%. Given Mediclinic International's higher probable upside, analysts clearly believe Mediclinic International is more favorable than Dechra Pharmaceuticals.

Dividends

Mediclinic International pays an annual dividend of GBX 0.03 per share and has a dividend yield of 0.0%. Dechra Pharmaceuticals pays an annual dividend of GBX 0.34 per share and has a dividend yield of 0.0%. Mediclinic International pays out -0.1% of its earnings in the form of a dividend. Dechra Pharmaceuticals pays out 0.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Mediclinic International is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Dechra Pharmaceuticals beats Mediclinic International on 5 of the 9 factors compared between the two stocks.

Mediclinic International (LON:MDC) and Abcam (LON:ABC) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership.

Dividends

Mediclinic International pays an annual dividend of GBX 0.03 per share and has a dividend yield of 0.0%. Abcam pays an annual dividend of GBX 0.04 per share and has a dividend yield of 0.0%. Mediclinic International pays out -0.1% of its earnings in the form of a dividend. Abcam pays out -3.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Mediclinic International and Abcam, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mediclinic International03102.25
Abcam05102.17

Mediclinic International presently has a consensus target price of GBX 301, suggesting a potential downside of 1.44%. Abcam has a consensus target price of GBX 1,402, suggesting a potential downside of 4.76%. Given Mediclinic International's stronger consensus rating and higher probable upside, analysts clearly believe Mediclinic International is more favorable than Abcam.

Profitability

This table compares Mediclinic International and Abcam's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mediclinic InternationalN/AN/AN/A
AbcamN/AN/AN/A

Earnings and Valuation

This table compares Mediclinic International and Abcam's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mediclinic International£2.98 billion0.76N/AGBX (56.20)-5.43
Abcam£269.30 million12.39N/AGBX (0.90)-1,635.56

Abcam is trading at a lower price-to-earnings ratio than Mediclinic International, indicating that it is currently the more affordable of the two stocks.

Summary

Mediclinic International beats Abcam on 5 of the 8 factors compared between the two stocks.

Genus (LON:GNS) and Mediclinic International (LON:MDC) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, profitability and institutional ownership.

Dividends

Genus pays an annual dividend of GBX 0.29 per share and has a dividend yield of 0.0%. Mediclinic International pays an annual dividend of GBX 0.03 per share and has a dividend yield of 0.0%. Genus pays out 0.4% of its earnings in the form of a dividend. Mediclinic International pays out -0.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Mediclinic International is clearly the better dividend stock, given its higher yield and lower payout ratio.

Analyst Recommendations

This is a summary of recent ratings and target prices for Genus and Mediclinic International, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genus01102.50
Mediclinic International03102.25

Genus currently has a consensus target price of GBX 4,760, suggesting a potential downside of 5.37%. Mediclinic International has a consensus target price of GBX 301, suggesting a potential downside of 1.44%. Given Mediclinic International's higher possible upside, analysts plainly believe Mediclinic International is more favorable than Genus.

Profitability

This table compares Genus and Mediclinic International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GenusN/AN/AN/A
Mediclinic InternationalN/AN/AN/A

Earnings and Valuation

This table compares Genus and Mediclinic International's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genus£566.40 million5.80N/AGBX 73.6068.34
Mediclinic International£2.98 billion0.76N/AGBX (56.20)-5.43

Mediclinic International is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

BTG (LON:BTG) and Mediclinic International (LON:MDC) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, profitability and institutional ownership.

Analyst Recommendations

This is a summary of recent ratings and target prices for BTG and Mediclinic International, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BTG0000N/A
Mediclinic International03102.25

Mediclinic International has a consensus target price of GBX 301, suggesting a potential downside of 1.44%.

Profitability

This table compares BTG and Mediclinic International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BTGN/AN/AN/A
Mediclinic InternationalN/AN/AN/A

Valuation and Earnings

This table compares BTG and Mediclinic International's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BTG£914.10 million0.00N/AGBX 28.50N/A
Mediclinic International£2.98 billion0.76N/AGBX (56.20)-5.43

Mediclinic International is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks.


Mediclinic International Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Hikma Pharmaceuticals logo
HIK
Hikma Pharmaceuticals
1.6$2,323.00+0.6%£5.36 billion£2.34 billion17.72
ConvaTec Group logo
CTEC
ConvaTec Group
1.0$230.50+2.3%£4.62 billion£1.89 billion56.22
Dechra Pharmaceuticals logo
DPH
Dechra Pharmaceuticals
0.9$4,114.00+0.7%£4.45 billion£566.40 million99.37
Abcam logo
ABC
Abcam
0.5$1,472.00+1.8%£3.34 billion£269.30 million-1,635.56
Genus logo
GNS
Genus
1.3$5,030.00+0.2%£3.28 billion£566.40 million68.34
BTG logo
BTG
BTG
0.7N/AN/A£3.26 billion£914.10 million29.47
UDG Healthcare logo
UDG
UDG Healthcare
1.5$855.00+0.7%£2.15 billion£1.28 billion32.02Gap Up
Indivior logo
INDV
Indivior
1.6$153.00+0.2%£1.12 billion£674 million17.19Gap Up
Clinigen Group logo
CLIN
Clinigen Group
1.4$837.00+0.2%£1.11 billion£518.70 million86.29
PureTech Health logo
PRTC
PureTech Health
1.5$387.00+2.3%£1.11 billion£11.77 million276.43News Coverage
Gap Down
Oxford Biomedica logo
OXB
Oxford Biomedica
0.8$1,042.00+0.4%£858.66 million£87.73 million-133.59Gap Up
MaxCyte logo
MXCT
MaxCyte
0.5$900.00+0.2%£854.24 million£26.17 million-73.77
Spire Healthcare Group logo
SPI
Spire Healthcare Group
1.0$202.50+0.7%£812.20 million£919.90 million-3.47
RENX
Renalytix AI
0.6$1,080.00+1.4%£788.92 million£400,000.00-55.38
UPR
Uniphar
1.3$257.96+1.5%£704.27 million£1.82 billion28.04
Vectura Group logo
VEC
Vectura Group
1.4$116.60+2.4%£695.12 million£190.60 million5.80News Coverage
Ergomed logo
ERGO
Ergomed
0.6$1,330.00+1.5%£648.38 million£86.39 million69.27
Advanced Medical Solutions Group logo
AMS
Advanced Medical Solutions Group
0.5$292.00+0.9%£629.39 million£86.80 million74.87
CareTech logo
CTH
CareTech
1.5$554.00+0.4%£627.68 million£429.97 million25.18
Avacta Group logo
AVCT
Avacta Group
0.5$241.20+2.8%£611.19 million£3.64 million-28.71News Coverage
Silence Therapeutics logo
SLN
Silence Therapeutics
0.7$605.00+0.8%£540.86 million£5.48 million-15.20Gap Up
Alliance Pharma logo
APH
Alliance Pharma
0.8$96.00+0.1%£512.65 million£129.80 million64.00
Consort Medical plc (CSRT.L) logo
CSRT
Consort Medical plc (CSRT.L)
0.9$1,010.00+0.5%£504.60 million£298.60 million127.85
SPEC
Inspecs Group
1.0$400.00+0.5%£409.76 million£47.58 million-31.75Upcoming Earnings
Benchmark logo
BMK
Benchmark
0.9$58.00+5.6%£388.69 million£109.90 million-13.49
Beximco Pharmaceuticals logo
BXP
Beximco Pharmaceuticals
0.5$86.50+0.0%£385.89 millionN/A0.00
EKF Diagnostics logo
EKF
EKF Diagnostics
1.1$69.60+2.0%£316.68 million£65.26 million29.00Insider Selling
Amryt Pharma logo
AMYT
Amryt Pharma
0.8$172.50+13.0%£308.92 million£182.61 million-3.65Analyst Report
High Trading Volume
News Coverage
Gap Down
CREO
Creo Medical
0.5$194.00+2.6%£306.40 million£8,154.00-15.65Gap Down
NCYT
Novacyt
0.6$412.60+0.6%£291.40 million£78.23 million7.97
Tristel logo
TSTL
Tristel
0.6$570.00+0.9%£268.25 million£33.80 million50.89
ORPH
Open Orphan
0.0$38.25+0.7%£256.05 million£10.57 million-11.95
ARIX
Arix Bioscience
0.8$190.00+0.0%£253.36 million£135.77 million2.14
ECO Animal Health Group logo
EAH
ECO Animal Health Group
0.9$362.50+0.0%£245.43 million£86.32 million72.50
ANGLE logo
AGL
ANGLE
0.4$113.50+0.4%£244.54 million£762,000.00-17.46
Synairgen logo
SNG
Synairgen
0.4$110.00+3.5%£219.91 million£79,000.00-21.57
Bioventix logo
BVXP
Bioventix
0.8$4,160.00+0.0%£216.69 million£10.38 million31.71
MGP
Medica Group
0.8$159.50+0.0%£195.21 million£41.55 million36.25
POLX
Polarean Imaging
0.5$89.00+0.0%£186.04 million£2.23 million-26.18
DDDD
4D pharma
0.6$102.00+8.4%£183.91 million£690,000.00-5.28
Redx Pharma logo
REDX
Redx Pharma
0.6$65.00+0.0%£178.03 million£5.69 million-12.04Gap Down
Scancell logo
SCLP
Scancell
0.6$21.60+7.6%£176.09 millionN/A-15.43
ANIC
Agronomics
0.5$34.00+7.4%£170.64 million£1.05 million-170.00High Trading Volume
Faron Pharmaceuticals Oy logo
FARN
Faron Pharmaceuticals Oy
0.6$330.00+2.6%£166.51 million£2.12 million-10.22
ANCR
Animalcare Group
0.7$276.00+0.7%£165.76 million£70.49 million690.00High Trading Volume
Gap Up
ONC
Oncimmune
0.4$233.00+1.3%£161.00 million£2.03 million-25.60
Tiziana Life Sciences logo
TILS
Tiziana Life Sciences
0.4$81.50+0.6%£158.61 millionN/A-14.82
Omega Diagnostics Group logo
ODX
Omega Diagnostics Group
0.3$83.00+13.7%£151.55 million£8.52 million-18.86
Mereo BioPharma Group plc (MPH.L) logo
MPH
Mereo BioPharma Group plc (MPH.L)
0.6N/AN/A£138.87 millionN/A-0.21News Coverage
Gap Down
Allergy Therapeutics logo
AGY
Allergy Therapeutics
0.9$21.60+0.5%£138.41 million£81.76 million21.60News Coverage
This page was last updated on 5/7/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.